secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088236
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024
--------------------------------------------------------------------------------

- Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.
- Cash and securities $273.8M as of June 30, 2024; expected to fund operations into 2027.
- Phase 3 REACH trial (losmapimod for FSHD) topline data expected by end of October 2024; 260 patients enrolled.
- Collaboration with Sanofi for ex-U.S. losmapimod; $80M upfront received in Q2.
- Phase 1b pociredir (SCD) advancing; cohorts at 12 mg and 20 mg once daily planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024088236/0000950170-24-088236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024088236/fulc-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer